Wat is de prijs voor Galera Therapeutics, Inc. (GRTX)

Het prijs van Galera Therapeutics, Inc. (GRTX) is $17.15

Wat is de marktkapitalisatie voor Galera Therapeutics, Inc. (GRTX)

Marktkapitalisatie voorGalera Therapeutics, Inc. (GRTX) is $6.51M

Galera Therapeutics, Inc. (GRTX) Aandelensplitsingen

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
2026-07-13	1:200	x0.005	x0.005

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

2026-07-13

1:200

x0.005

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land